A New Innovative Gene Therapy Targeting the European Market

Novartis (NVS) has received final marketing authorization from the European Commission (EC) on July 2, 2026, for Itvisma, a single-dose gene therapy for spinal muscular atrophy (SMA). This approval follows the positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) in April 2026. Itvisma is indicated for patients aged 2 years and older with SMA, including children, adolescents, and adults with 5q SMA. Itvisma works by replacing the defective SMN1 gene with a functional one. It is an intrathecal formulation, expanding the target population from the existing intravenous formulation, Zolgensma, which is indicated for younger children. This approval is a regulatory milestone that expands the application of gene therapy technology to all age groups, offering a single-dose treatment that can fundamentally improve the quality of life for patients with rare diseases who require lifelong management.

Improved Motor Function Demonstrated in Phase 3 Clinical Data

The key basis for this European approval is the results of the STEER (NCT05089656) study, a global Phase 3 clinical trial involving 126 patients with SMA type 2 aged 2 years and older who had not received prior treatment. In the clinical trial, the Itvisma group showed a 2.39-point improvement in the Hammersmith Functional Motor Scale Expanded (HFMSE) score, compared to 0.51 points in the placebo group, which was statistically significant (P=0.0074). In addition, sustained motor function development and maintenance were demonstrated in various indicators, including upper limb function assessment (RULM), and a consistent safety profile was confirmed in long-term follow-up. The clinical data scientifically demonstrate that the direct delivery of the active ingredient to the spinal tissue through a change in the direct administration route of the drug can achieve high clinical efficacy even in older patients.

Securing Exclusive Status and Prospects for Restructuring Competitive Landscape

The global SMA treatment market is valued at approximately $4.4 billion to $5.13 billion in 2024-2025 and is expected to grow rapidly to $13 billion to $23 billion in the early 2030s. Itvisma is poised to become a powerful game-changer, competing with Biogen's (BIIB) Spinraza and Roche's Evrysdi, the existing standard treatments in the market. Unlike existing treatments that require periodic administration, Itvisma is administered only once, which significantly improves patient convenience and has the potential to rapidly capture market share.

Challenges in Setting Ultra-High Prices and Securing Reimbursement

The biggest challenge for Itvisma to achieve commercial success is negotiating prices with health authorities in each European country and securing reimbursement coverage. Given that the administration cost of Zolgensma was approximately $2.1 million, Itvisma is also expected to be priced at a very high level, which could put significant financial pressure on health authorities. Novartis should actively propose innovative models such as performance-based installment payments or risk-sharing agreements to ensure early market penetration. The success of these negotiations will be a key factor in determining Itvisma's revenue growth and will also serve as an important precedent for future ultra-high-priced gene therapy markets.